Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

HemaSphere·2022
Same author

MYC multimers shield stalled replication forks from RNA polymerase.

Nature·2022
Same author

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Cancers·2022
Same author

Vitamin D Receptor Expression Is Significantly Decreased in Bone Metastases Compared to Matched Primary Breast Cancer Tumours.

Cancer investigation·2022
Same author

Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.

Cancers·2022
Same author

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022

Related Experiment Video

Updated: May 16, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Brett Collinge, Laura K Hilton, Jasper Wong

    Medrxiv : the Preprint Server for Health Sciences
    |March 31, 2025
    PubMed
    Summary

    High-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) is a rare and complex disease. Molecular profiling reveals a diverse landscape, with some tumors aligning with established lymphoma subtypes, aiding in diagnosis and trial eligibility.

    More Related Videos

    Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
    07:39

    Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

    Published on: January 7, 2019

    12.1K
    Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
    07:52

    Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

    Published on: January 9, 2019

    19.6K

    Related Experiment Videos

    Last Updated: May 16, 2025

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
    11:29

    HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

    Published on: July 20, 2016

    11.0K
    Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
    07:39

    Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

    Published on: January 7, 2019

    12.1K
    Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
    07:52

    Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

    Published on: January 9, 2019

    19.6K

    Area of Science:

    • Hematologic Oncology
    • Molecular Pathology
    • Genomic Characterization of Lymphoma

    Background:

    • High-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) presents diagnostic challenges due to rarity, evolving definitions, and reproducibility issues.
    • Existing molecular frameworks for diffuse large B-cell lymphoma (DLBCL-NOS) and Burkitt lymphoma (BL) provide a basis for comparison.
    • Understanding the molecular heterogeneity of HGBCL-NOS is crucial for accurate classification and treatment strategies.

    Purpose of the Study:

    • To molecularly characterize a cohort of 92 HGBCL-NOS tumors.
    • To compare the molecular features of HGBCL-NOS with DLBCL-NOS and BL.
    • To assess the utility of genetic classifiers in assigning HGBCL-NOS to established molecular subtypes.

    Main Methods:

    • Analysis of 92 HGBCL-NOS tumors alongside comparison cohorts of DLBCL-NOS and BL.
    • Application of cell-of-origin classification (GCB vs. ABC).
    • Utilized LymphGen genetic classifier for DLBCL-NOS and a DLBCL-NOS vs. BL classifier.
    • Performed centralized pathology review for diagnostic reclassification.

    Main Results:

    • HGBCL-NOS exhibits a heterogeneous molecular landscape, with features overlapping DLBCL-NOS and enriched for BL characteristics.
    • 59% of HGBCL-NOS were GCB-like, and 25% were ABC-like; LymphGen classified 34% of cases, including MCD subtypes within ABCs.
    • Distinctive features of HGBCL-NOS compared to DLBCL-NOS include higher rates of MYC-rearrangement (47%), dark zone signature (DZsig) expression (45%), and mutations in ID3, MYC, CCND3, and TP53, aligning with BL.
    • A significant proportion of DZsig+ tumors were classified as BL-like (53%), while DZsig-GCB tumors were predominantly DLBCL-like (95%).
    • Pathology review reclassified nearly half of the tumors, but did not reveal a more homogenous HGBCL-NOS population.

    Conclusions:

    • Molecular testing can assign a subset of HGBCL-NOS cases to established lymphoma categories.
    • The molecular heterogeneity and diagnostic challenges underscore the need for broader inclusion of HGBCL-NOS in biomarker-driven DLBCL clinical trials.
    • HGBCL-NOS represents a spectrum of molecularly defined entities rather than a single entity.